February 21, 2020

TissueTech Launches Physician Portal to Help Providers Make Meaningful Patient Care Decisions

Online platform gives physicians access to clinical resources and tools to make informed decisions and enhance patient outcomes

Miami, FL –February 22, 2020 – TissueTech, Inc., a pioneer and market leader in the development and clinical application of human birth tissue products, announced today the launch of a web-based physician portal to support clinical decision-making when using Amniox or BioTissue human birth tissue products. The portal is easy to navigate and populated with a repository of scientific and clinical information.

Physician users will also find a host of value-added services designed to afford them with the convenience of one-stop-shopping for the tools and resources needed to optimize practice performance and profitability. Relevant information includes coding guides and coverage policies to ensure proper claim submission and rapid reimbursement, peer-reviewed clinical research papers, product support literature, and patient materials.

“We’ve built this portal to give our physician customers the tools they need to be confident when leveraging our platform technology,” said Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and co-founder of TissueTech. “The portal is designed for physicians who want to become more familiar with Amniox and BioTissue products to take meaningful clinical action that benefits their patients.”

Physicians can access the portal through the TissueTech, Amniox or BioTissue websites, or they can contact their Amniox or BioTissue sales representative for assistance.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at https://biotissue.com/.



Related Content